Evidence map›Paper›PMID 37033545›Full record

ArticleCureus2023

MicroRNAs in the Diagnosis of Malignancy of Supratentorial Brain Gliomas and Prognosis of Disease Progression.

Evgeny V Stupak, Yulia A Veryasikina, Sergey E Titov, Arsen S Askandaryan, James C Hiana, Igor F Zhimulyov, Vyacheslav V Stupak

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Evgeny V StupakDepartment of Neurosurgery, Novosibirsk Research Institute of Traumatology and Orthopedics n.a. Ya.L. Tsivyan, Novosibirsk, RUS.
Yulia A VeryasikinaLaboratory of Genetics, Institute of Molecular and Cell Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, RUS.
Sergey E TitovLaboratory of Genetics, Institute of Molecular and Cell Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, RUS.
Arsen S AskandaryanDepartment of Psychiatry, Jamaica Hospital Medical Center, New York City, USA.
James C HianaDepartment of Neurology, State University of New York Downstate Medical Center, New York City, USA.
Igor F ZhimulyovLaboratory of Genetics, Institute of Molecular and Cell Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, RUS.
Vyacheslav V StupakDepartment of Neurosurgery, Novosibirsk Research Institute of Traumatology and Orthopedics n.a. Ya.L. Tsivyan, Novosibirsk, RUS.
Novosibirsk Scientific Research Institute of Traumatology and Orthopedics. Ya.L. Tsivyan · RUState University of New York · USInstitute of Molecular Genetics · RUState Research Center of Virology and Biotechnology VECTOR · RUSUNY Downstate Health Sciences University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe study of brain tumors has shown that microRNAs can act as both oncogenes and tumor suppressors and, consequently, can be used as biomarkers for the diagnosis and prognosis of such tumors. Thus, big interest arises in the role of microRNA and its part in oncogenesis in the human brain to find key molecules that can act as tumor markers for diagnostic and prognostic purposes, as well as potential therapeutic agents. STUDY

aimThe sim of this study was to assess histological, molecular, and genetic metrics in patients with supratentorial gliomas, and indicate diagnostic and prognostic abilities of microRNA usage as biomarkers of the grade of malignancy of the tumor. MATERIALS AND

methodsClinical and genetic studies were performed in 107 operated patients with supratentorial gliomas of different malignancies. The expression levels of 10 microRNAs (-16, -21¸ -31, -124, - 125b, -181b, -191, -221, -223, and -451) were analyzed using real-time polymerase chain reaction (PCR). The results were analyzed statistically using Statistica 12.0 (Statistica, Hamburg, Germany) and GraphPad Prism 9 software (GraphPad Software Inc., Boston, Massachusetts, United States).

resultsBased on a comprehensive statistical analysis involving the database of the clinical results of treatment of all 107 patients (combined treatment methods, quality of life, and survival) and microRNA expression levels, specific profiles of microRNA expression typical of different histotypes of gliomas of different malignancy were identified, the prognostic significance of the studied microRNAs as potential predictors of survival in patients with brain gliomas was determined, and microRNAs with the highest prognostic value were identified among them.

Indexed as

brain gliomasgliomas of different malignancymicrornamicrorna expressionmolecular genetic studypredictor of survivalreal-time pcr

Identifiers

PMID37033545
PMCPMC10081567
OpenAlexW4323543533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.